News

Specifically, Affilogic and Takeda, through its research center in San Diego, California, will leverage their respective competencies to validate and optimize Nanofitins® that enable Takeda to deliver biotherapeutic

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune,

The selected compounds come from a library of small molecules, discovered as part of Turing's research efforts in toxoplasmosis, with significantly improved potency and selectivity over current treatments

The announcement was made at an event in San Francisco, US. The money comes from the Chan Zuckerberg Initiative the couple has started last year for advancing human

Under the five-year, multi-target research partnership, the companies will develop several clinical candidates for the treatment of chronic kidney disease in diabetes patients. Both parties will contribute novel

Emma will succeed Andrew Witty as GSK CEO, when he retires on 31March 2017. Emma will join the GSK Board of Directors from 1 January 2017. Emma is currently

Validation of the application confirms the submission is complete and begins the EMA’s centralized review process. Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb, said: “The high frequency

In its filing in the US district court of Delaware, Sanofi claims that Merck Sharp & Dohme Corp. violated 10 patents held by it, including ones for its

This indication is based on an increase in dystrophin in skeletal muscles observed in some patients treated with EXONDYS 51. A clinical benefit of EXONDYS 51 has not